ATCG is devoted to originating innovative treatment concepts for patients with glioblastoma.

Glioblastoma is the most common malignant intrinsic brain tumor in adults and yearly affects approximately 13 500 newly diagnosed patients in Europe, 10 000 patients in the U.S.A. and calculationally around 240 000 patients globally. First-line treatment consists of state-of-the-art neurologically safe (supra-)maximal resection (observing onco-functional balance), concomitant radiochemotherapy, additive chemotherapy and alternating electrical fields. Virtually all patients experience tumor progression or recurrence within an average period of 9 months after diagnosis due to intrinsic or acquired tumor cell resistance against first-line treatment modalities, leaving patients with few if any effective therapeutic options at that point. Against this background, ATCG is devoted to originating innovative treatment concepts for patients with newly diagnosed, progressive or recurrent glioblastoma. Our portfolio currently comprises four different approaches in development. ATCG is a start-up actively looking for investors.